Akiram Therapeutics

About:

Advancing radiotherapeutics to treat solid tumors

Website: https://akiramtherapeutics.se/

Top Investors: Sciety

Description:

Akiram Therapeutics is a Swedish biotech company focused on the development of targeted radioimmunotherapy for cancer, which is based on a proprietary antibody targeting the cancer marker CD44v6 combined with a radiation component. The therapy has generated strong preclinical results in cancer models in conditions that currently lack effective treatments. With the potential for its drug candidate to be classified as an orphan drug and recognized as first-in-class, the company is dedicated to advancing research in this field, including indications in head and neck cancer, AML (Acute Myeloid Leukemia), lung cancer, and aggressive thyroid cancer. Headquartered in Uppsala, Sweden, Akiram Therapeutics is staffed with experts in radiation science research, cancer precision medicine, and drug development.

Total Funding Amount:

67.9M SEK

Headquarters Location:

Uppsala, Uppsala Lan, Sweden

Founded Date:

2021-06-10

Contact Email:

info(AT)akiramtherapeutics.se

Founders:

Anja Mortensen, Fredrik Frejd, Marika Nestor

Number of Employees:

1-10

Last Funding Date:

2022-11-22

IPO Status:

Private

Industries:

© 2025 bioDAO.ai